Tesis sobre el tema "Drug Side Effect Prediction"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 21 mejores tesis para su investigación sobre el tema "Drug Side Effect Prediction".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore tesis sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Wang, Chen. "High-throughput prediction and analysis of drug-protein interactions in the druggable human proteome". VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5509.
Texto completoBellón, Molina Víctor. "Prédiction personalisée des effets secondaires indésirables de médicaments". Thesis, Paris Sciences et Lettres (ComUE), 2017. http://www.theses.fr/2017PSLEM023/document.
Texto completoAdverse drug reaction (ADR) is a serious concern that has important health and economical repercussions. Between 1.9%-2.3% of the hospitalized patients suffer from ADR, and the annual cost of ADR have been estimated to be of 400 million euros in Germany alone. Furthermore, ADRs can cause the withdrawal of a drug from the market, which can cause up to millions of dollars of losses to the pharmaceutical industry.Multiple studies suggest that genetic factors may play a role in the response of the patients to their treatment. This covers not only the response in terms of the intended main effect, but also % according toin terms of potential side effects. The complexity of predicting drug response suggests that machine learning could bring new tools and techniques for understanding ADR.In this doctoral thesis, we study different problems related to drug response prediction, based on the genetic characteristics of patients.We frame them through multitask machine learning frameworks, which combine all data available for related problems in order to solve them at the same time.We propose a novel model for multitask linear prediction that uses task descriptors to select relevant features and make predictions with better performance as state-of-the-art algorithms. Finally, we study strategies for increasing the stability of the selected features, in order to improve interpretability for biological applications
Amanzadi, Amirhossein. "Predicting safe drug combinations with Graph Neural Networks (GNN)". Thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-446691.
Texto completoVillafranca, Steven Wayne. "The effect of early psychostimulant treatment on abuse liability and dopamine receptors". CSUSB ScholarWorks, 2005. https://scholarworks.lib.csusb.edu/etd-project/2824.
Texto completoDiaz, Boada Juan Sebastian. "Polypharmacy Side Effect Prediction with Graph Convolutional Neural Network based on Heterogeneous Structural and Biological Data". Thesis, KTH, Numerisk analys, NA, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-288537.
Texto completoFör att minska dödligheten och sjukligheten hos patienter som lider av komplexa sjukdomar är det avgörande att kunna förutsäga biverkningar från polyfarmaci. Att experimentellt förutsäga biverkningarna är dock ogenomförbart på grund av det stora antalet möjliga läkemedelskombinationer, vilket lämnar in silico-verktyg som det mest lovande sättet att lösa detta problem. Detta arbete förbättrar prestandan och robustheten av ett av det senaste grafiska faltningsnätverken som är utformat för att förutsäga biverkningar från polyfarmaci, genom att mata det med läkemedel-protein-nätverkets komplexitetsegenskaper. Ändringarna involverar också skapandet av en direkt pipeline för att återge resultaten och testa den med olika dataset.
Zayed, Aref. "Development of ICP-MS assays for the study and prediction of the efficacy and side effects of Pt-based drugs in cancer chemotherapy". Thesis, Loughborough University, 2012. https://dspace.lboro.ac.uk/2134/9446.
Texto completoGauthier, Kelly J. "Length of Hospital Stay, Delirium and Discharge Status Outcomes Associated With Anticholinergic Drug Use in Elderly Hospitalized Dementia Patients". VCU Scholars Compass, 2006. http://hdl.handle.net/10156/1704.
Texto completoWinter, Lara. "Characterisation of the neurosteroid analgesic alphadolone". Monash University, Dept. of Anaesthesia, 2004. http://arrow.monash.edu.au/hdl/1959.1/9669.
Texto completoKucher, Kellie Lynn. "Effect of preweanling methylphenidate exposure on the induction, extinction and reinstatement of morphine-Induced conditioned place preference in rats". CSUSB ScholarWorks, 2005. https://scholarworks.lib.csusb.edu/etd-project/2892.
Texto completoGouws, Stephanus Andries. "The impact of hospital surveillance programmes on the incidence of adverse drug reaction reporting in a South African teaching hospital". Master's thesis, University of Cape Town, 1989. http://hdl.handle.net/11427/27186.
Texto completoIsreb, Abdullah. "The use of solubility parameters to predict the behaviour of a co-crystalline drug dispersed in a polymeric vehicle : approaches to the prediction of the interactions of co-crystals and their components with hypromellose acetate succinate and the characterization of that interaction using crystallographic, microscopic, thermal, and vibrational analysis". Thesis, University of Bradford, 2012. http://hdl.handle.net/10454/5525.
Texto completoPrague, Mélanie. "Utilisation des modèles dynamiques pour l'optimisation des traitements des patients infectés par le VIH". Thesis, Bordeaux 2, 2013. http://www.theses.fr/2013BOR22056.
Texto completoMost HIV-infected patients viral loads can be made undetectable by highly active combination of antiretroviral therapy (cART), but there are side effects of treatments. The use of dynamic mechanistic models based on ordinary differential equations (ODE) has greatly improved the knowledge of the dynamics of HIV and of the immune system and can be considered for personalization of treatment. The aim of these PhD works is to improve the statistical techniques for estimating parameters in dynamic mechanistic models so as to elaborate strategies for monitoring and optimizing treatments. We present an algorithm and program called NIMROD using Bayesian inference based on the maximization of the penalized likelihood. Then, we show the power of dynamic mechanistic approaches for the evaluation of treatment effects compared to methods based on the descriptive analysis of the biomarkers trajectories. Next, we build the “target cells model “, an ODE system of the dynamics between the HIV and CD4. We demonstrate it has good predictive capabilities. We build a proof of concept for drug dose individualization. It consists in tuning the dose of the patient based on his reaction to the previous doses using a Bayesian update procedure. Finally, we introduce the possibility of designing an individualized change of cART. This work involves the quantification of in vivo effects of cART using in vitro antiviral activity indicators. We discuss the validity of the results and the further steps needed for the integration of these methods in clinical practice
Bongini, Pietro. "Graph Neural Networks for Molecular Data". Doctoral thesis, 2022. http://hdl.handle.net/2158/1274291.
Texto completoChi, Chih Chien y 紀旨倩. "Predicting Drug Side Effects and Targets Using Machine Learning Approaches - A Case Study on Antidepressants". Thesis, 2016. http://ndltd.ncl.edu.tw/handle/r34a32.
Texto completo國立清華大學
資訊系統與應用研究所
104
Depression is a life-threatening mental health disorder which is expected to be the second leading cause of psychosocial disability throughout the world by 2020 and will become the largest contributor to lost work productivity by 2030 as reported by World Health Organization (WHO, 2012). Despite the availability of various therapeutic options, the underlying pathological mechanisms remain unclear. The important concerns with antidepressants are delayed therapeutic response and insufficient efficacy. With a wide range of adverse effects, there is no doubt a large unmet need for better pharmaceutical treatment. The purpose of our study is to develop a computational approach to investigate potential side effects and targets of antidepressants, hoping to provide support for better strategies for the future of drug development and therapy. We presented an aggregation framework to predict unknown side effects and hidden targets from 816 drugs by adopting 653 chemical, 984 biological and 6,111 phenotypic features. Among four machine learning-based algorithms, we found that the aggregation random forest model achieved best in overall performance. Hence, we used this computational approach to predict the potential candidates for antidepressants. We conducted the case study using 15 depression-related drugs, including 9 first generation, 5 second generation antidepressants and 1 muscle relaxant that has a structure similar to tricyclic antidepressant (TCA). The in silico model obtained promising results with AUROC score of 0.9140834, AUPR score of 0.5185952 for side effects prediction and AUROC score of 0.9513566, AUPR score of 0.3101223 for targets prediction.
Yun-Chu-Chen y 陳韻竹. "Effects of quercetin on the antitumor and side effect of chemotherapy drug-cisplatin". Thesis, 2015. http://ndltd.ncl.edu.tw/handle/29268310115564743895.
Texto completo中山醫學大學
營養學研究所
103
Part 1. Cisplatin (CIS) is a widely used chemotherapy drug for human cancers, including lung cancer. Despite its significant antitumor activity, the side effects limit its use. Quercetin (Q), a flavonoid present abundantly in plants, has been shown to may increase the antitumor effects of some anti-cancer drugs and to decrease their harmful effects. In this study, we first used a xenograft model to investigate the effects of quercetin on the antitumor and side effects of CIS. Male nude mice were injected with A549 cells (human lung cancer cell line) into the flank. After 4 weeks, the tumor-bearing mice were randomly treated with cisplatin (2 or 5 mg/kg, once a week; CIS2 and CIS5, respectively) alone, or CIS2 in combination with quercetin for 12 weeks. Quercetin was given by a quercetin containing diet (0.1% or 1% quercetin diet; LQ and HQ, respectively) or by intraperitoneal injection (10 mg/kg, 3 times a week; IQ). The results showed that CIS2+HQ and CIS2+IQ rather than CIS2 alone or CIS2+LQ significantly inhibited tumor growth. The effects of CIS2+IQ and CIS2+HQ were similar to that of CIS5. We found that CIS2 in combination a Q containing diet or IQ tended to decrease plasma TBARs levels as well as proinflammatory cytokines in plasma and in tumors, especially IQ. Quercetin containing diets and IQ also significantly increased the total quercetin concentration in tumor tissues in an order HQ>LQ and IQ. In addition, quercetin containing diets and IQ tended to increase gastrocnemius muscle, epididymal fat weight and bone marrow cell number compared to CIS2. Most the efficiencies of IQ were the best. CIS2 decreased the neutrophil count and increased the lymphocyte count. Quercetin tended to suppress these effects of cisplatin. In addition, CIS in combination with quercetin treatment significantly increase the platelet count, while CIS alone had no effect. However, CIS significantly reduced the red blood cell count and quercetin did not recover such an effect of CIS. The results of the present study demonstrated that quercetin not only increase the antitumor effect of cisplatin, but also reduce some of the side effects of cisplatin in vivo. Part 2. We found that the enhancing effect of IQ on the antitumor effect of CIS was better than that of quercetin from diet. We then compared the effect of quercetin and its metabolites, quercetin-3-glucuronide (G), at 2 μM and 5 μM on the anti-growth effect of CIS (1 μM) in A549 cells and explored the possible mechanisms. The results showed that CIS+Q and CIS+G enhanced CIS-induced cells growth arrest in A549 cells in a dose- and time-dependent manner. The combined inhibition efficiency of CIS+Q on cell growth was greater than that of the CIS+G at the same dose. Furthermore, we found that CIS induced cell cycle arrest in G2/M phase, and quercetin-3-glucuronide rather than quercetin significantly increased such an effect of CIS. However, CIS+Q significantly increased the cells in sub-G1 phase, indicating CIS+Q inducing apoptosis. CIS+Q also significantly increase caspase-3 activity, while cisplatin or CIS+G had no significant effect. We determined the expression of p21 and p53, which are associated with cell cycle arrest and apoptosis, in treated cells. The result showed that CIS in combination with Q quercetin or quercetin-3-glucuronide significantly increased p21 and p53 protein expression earlier than CIS alone. The effect of CIS+Q was better than that of CIS+G. In conclusion, quercetin has a better efficiency than quercetin-3-glucuronide to enhance the suppressed effect of CIS on the growth of A549 cells, which is in agreement with our in vivo findings. The results also suggest that quercetin and quercetin-3-glucuronide exert their effect may through increasing the expression of p21 and p53, which in turn inducing cell cycle arrest and apoptosis.
Tu, Wei-Ming y 涂偉銘. "Investigation of doxorubicin-loaded redox-responsive silica-Au drug nanocarrier for cancer inhibition and side effect mitigation in a zebrafish tumor model". Thesis, 2016. http://ndltd.ncl.edu.tw/handle/28015184474832617105.
Texto completo國立交通大學
應用化學系碩博士班
105
Despite the advancement in medicine, cancer still ranked first in the top ten causes of death. Chemotherapy has been the most common strategy to treat cancer. However, its non-specificity led to severe side effects in patients, as a result, the tolerant dosage was limited and the therapeutic effect could be reduced. The drug-loaded nanocarriers thus were employed to enable targeted delivery by selective ligand functionalization, improving the therapeutic efficacy. Doxorubicin is a well-known anti-cancer drug which is effective to several types of carcinoma but with severe and irreversible cardiotoxicity thereby hindering its usage. In this study, we developed a novel silica-gold nanocomposite Tf-DOX-ReSi-Au NPs in which the disulfide-linked redox-responsive silica (ReSi) was functionalized on the surface of gold nanoparticles (Au NPs, 13 nm), followed by the electrostatic adsorption of doxorubicin (DOX). Transferrin (Tf) served as selective ligand with high affinity to its receptor expressed predominantly in carcinomas. The release of DOX was then triggered upon high concentration of glutathione stimuli to reduce the disulfide bond embedded in the nanocomposite. The zebrafish tumor model was established in the study to evaluate the biocompatibility of nanocomposite in vivo. Tf-DOX-ReSi-Au NPs has found to be more effective in the inhibition of tumor growth than that of free DOX. Moreover, using the laser scanning confocal microscope, a 3D zebrafish heart model was constructed to investigate the cardiovascular functions after free drug and the nanocomposites treatment. Tf-DOX-ReSi-Au NPs revealed insignificant cardiotoxicity and side effects compared with that in free DOX.
Han, Xu. "Identification and mechanistic investigation of clinically important myopathic drug-drug interactions". Thesis, 2014. http://hdl.handle.net/1805/5275.
Texto completoDrug-drug interactions (DDIs) refer to situations where one drug affects the pharmacokinetics or pharmacodynamics of another. DDIs represent a major cause of morbidity and mortality. A common adverse drug reaction (ADR) that can result from, or be exacerbated by DDIs is drug-induced myopathy. Identifying DDIs and understanding their underlying mechanisms is key to the prevention of undesirable effects of DDIs and to efforts to optimize therapeutic outcomes. This dissertation is dedicated to identification of clinically important myopathic DDIs and to elucidation of their underlying mechanisms. Using data mined from the published cytochrome P450 (CYP) drug interaction literature, 13,197 drug pairs were predicted to potentially interact by pairing a substrate and an inhibitor of a major CYP isoform in humans. Prescribing data for these drug pairs and their associations with myopathy were then examined in a large electronic medical record database. The analyses identified fifteen drug pairs as DDIs significantly associated with an increased risk of myopathy. These significant myopathic DDIs involved clinically important drugs including alprazolam, chloroquine, duloxetine, hydroxychloroquine, loratadine, omeprazole, promethazine, quetiapine, risperidone, ropinirole, trazodone and simvastatin. Data from in vitro experiments indicated that the interaction between quetiapine and chloroquine (risk ratio, RR, 2.17, p-value 5.29E-05) may result from the inhibitory effects of quetiapine on chloroquine metabolism by cytochrome P450s (CYPs). The in vitro data also suggested that the interaction between simvastatin and loratadine (RR 1.6, p-value 4.75E-07) may result from synergistic toxicity of simvastatin and desloratadine, the major metabolite of loratadine, to muscle cells, and from the inhibitory effect of simvastatin acid, the active metabolite of simvastatin, on the hepatic uptake of desloratadine via OATP1B1/1B3. Our data not only identified unknown myopathic DDIs of clinical consequence, but also shed light on their underlying pharmacokinetic and pharmacodynamic mechanisms. More importantly, our approach exemplified a new strategy for identification and investigation of DDIs, one that combined literature mining using bioinformatic algorithms, ADR detection using a pharmacoepidemiologic design, and mechanistic studies employing in vitro experimental models.
Huang, Hui. "System biology modeling : the insights for computational drug discovery". Thesis, 2014. http://hdl.handle.net/1805/5612.
Texto completoTraditional treatment strategy development for diseases involves the identification of target proteins related to disease states, and the interference of these proteins with drug molecules. Computational drug discovery and virtual screening from thousands of chemical compounds have accelerated this process. The thesis presents a comprehensive framework of computational drug discovery using system biology approaches. The thesis mainly consists of two parts: disease biomarker identification and disease treatment discoveries. The first part of the thesis focuses on the research in biomarker identification for human diseases in the post-genomic era with an emphasis in system biology approaches such as using the protein interaction networks. There are two major types of biomarkers: Diagnostic Biomarker is expected to detect a given type of disease in an individual with both high sensitivity and specificity; Predictive Biomarker serves to predict drug response before treatment is started. Both are essential before we even start seeking any treatment for the patients. In this part, we first studied how the coverage of the disease genes, the protein interaction quality, and gene ranking strategies can affect the identification of disease genes. Second, we addressed the challenge of constructing a central database to collect the system level data such as protein interaction, pathway, etc. Finally, we built case studies for biomarker identification for using dabetes as a case study. The second part of the thesis mainly addresses how to find treatments after disease identification. It specifically focuses on computational drug repositioning due to its low lost, few translational issues and other benefits. First, we described how to implement literature mining approaches to build the disease-protein-drug connectivity map and demonstrated its superior performances compared to other existing applications. Second, we presented a valuable drug-protein directionality database which filled the research gap of lacking alternatives for the experimental CMAP in computational drug discovery field. We also extended the correlation based ranking algorithms by including the underlying topology among proteins. Finally, we demonstrated how to study drug repositioning beyond genomic level and from one dimension to two dimensions with clinical side effect as prediction features.
Zottmann, Claudia. "EKT und unerwünschte Ereignisse – eine retrospektive Analyse an der Universitätsmedizin Göttingen". Doctoral thesis, 2017. http://hdl.handle.net/11858/00-1735-0000-002B-7D51-3.
Texto completoPrague, Melanie. "Utilisation des modèles dynamiques pour l'optimisation des traitements des patients infectés par le VIH". Thesis, 2013. http://www.theses.fr/2013BOR22056/document.
Texto completoMost HIV-infected patients viral loads can be made undetectable by highly active combination of antiretroviral therapy (cART), but there are side effects of treatments. The use of dynamic mechanistic models based on ordinary differential equations (ODE) has greatly improved the knowledge of the dynamics of HIV and of the immune system and can be considered for personalization of treatment. The aim of these PhD works is to improve the statistical techniques for estimating parameters in dynamic mechanistic models so as to elaborate strategies for monitoring and optimizing treatments. We present an algorithm and program called NIMROD using Bayesian inference based on the maximization of the penalized likelihood. Then, we show the power of dynamic mechanistic approaches for the evaluation of treatment effects compared to methods based on the descriptive analysis of the biomarkers trajectories. Next, we build the “target cells model “, an ODE system of the dynamics between the HIV and CD4. We demonstrate it has good predictive capabilities. We build a proof of concept for drug dose individualization. It consists in tuning the dose of the patient based on his reaction to the previous doses using a Bayesian update procedure. Finally, we introduce the possibility of designing an individualized change of cART. This work involves the quantification of in vivo effects of cART using in vitro antiviral activity indicators. We discuss the validity of the results and the further steps needed for the integration of these methods in clinical practice
McCanna, David. "Development of Sensitive In Vitro Assays to Assess the Ocular Toxicity Potential of Chemicals and Ophthalmic Products". Thesis, 2009. http://hdl.handle.net/10012/4338.
Texto completo